Compounds as RET Inhibitors

By providing novel compounds, formula (I) and formula (A) and their pharmaceutical compositions, the problems of insufficient selectivity and drug resistance mutations of existing RET inhibitors are solved, and efficient treatment of RET-driven cancer is achieved, reducing the risk of side effects .

CN113943285BActive Publication Date: 2024-12-06CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202110804923.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-07-17
Filing Date
2021-07-16
Publication Date
2024-12-06
Estimated Expiration
2041-07-16

AI Technical Summary

Technical Problem

Existing RET inhibitors have insufficient selectivity and drug-resistant mutation problems in clinical applications, resulting in poor efficacy in RET-driven cancer treatment and trigger side effects. There is no second generation with high selectivity and effective drug-resistant mutations. RET inhibitors are approved for marketing.

Method used

A novel compound is provided, compounds of formula (I) and formula (A) and their stereoisomers and their pharmaceutically acceptable salts, with highly selective inhibition of RET kinase through specific structural composition and synthetic routes. and its drug-resistant mutation form, such as RET (V804M), and provide treatment options through various routes of administration such as oral, topical, etc.

Benefits of technology

These compounds show good RET kinase inhibitory activity and tumor cell inhibition effect, have excellent in vivo pharmacokinetic properties, can effectively inhibit RET-driven cancer cells, reduce side effects, improve treatment selectivity and drug resistance countermeasures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113943285B_ABST
    Figure CN113943285B_ABST
Patent Text Reader

Abstract

The present application relates to compounds as RET inhibitors, specifically to compounds represented by formula (I), stereoisomers thereof and pharmaceutically acceptable salts thereof, preparation methods thereof, pharmaceutical compositions thereof and their use in the preparation of drugs for preventing or treating diseases mediated by abnormal RET activity. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the rights and priority of Chinese invention patent application No. 202010691486.3 filed with the State Intellectual Property Office of the People's Republic of China on July 17, 2020, the entire contents of which are hereby incorporated by reference into this document in their entirety. Technical Field

[0003] The present application relates to compounds that serve as RET inhibitors, specifically to compounds represented by formula (I), compounds represented by formula (A), stereoisomers thereof and pharmaceutically acceptable salts thereof, preparation methods thereof, pharmaceutical compositions thereof and use thereof in the preparation of drugs for preventing or treating diseases mediated by abnormal RET activity. Background Art

[0004] RET (Rearranged during Transfection) is a membrane receptor tyrosine kinase encoded by the proto-oncogene RET gene located on chromosome 10. Its ligands are GNDF family proteins (GFLs), such as GDNF, NTRN, ARTN and PSPN. However, unlike other receptor tyrosine kinases, RET does not bind directly to its ligands. GDNF, NTRN, ARTN and PSPN bind to the co-receptor GFRα of RET to form the GFL-GFRα complex, which mediates the dimerization of RET and the autophosphorylation of tyrosine residues in the intracellular domain of RET, activates the cascade reaction of downstream pathways such as MAPK, PI3K, JAK-STAT, PKA and PKC, and ultimately regulates the proliferation and differentiation levels of cells. Therefore, abnormal upregulation of RET activity will cause diseases such as cancer.

[0005] RET can be abnormally activated through two pathways: point mutation and gene fusion. Point mutations at the kinase end of the RET intracellular domain increase the catalytic phosphorylation activity of RET, such as E768D, L790F, V804M, etc.; point mutations in the extracellular domain can promote the formation of intermolecular disulfide bonds, causing ligand-independent dimerization of RET, thereby leading to autophosphorylation of RET. Gene fusion of RET can easily lead to the fusion of the RET kinase end with the partner protein with a dimer end to form a hybrid protein with RET catalytic activity, leading to RET ligand-independent dimerization and stimulating RET catalytic activity. RET fusion genes that have been discovered so far include RET-CCDC6, RET-PRKAR1A, RET-GOLGA5, and RET-RFG9. Clinical studies have shown that many cancers, such as thyroid cancer, non-small cell lung cancer, colon cancer and breast cancer, are driven by RET. Among them, RET-driven papillary thyroid cancer, medullary thyroid cancer and non-small cell lung cancer account for a relatively high proportion, accounting for 11%, 60% and 2% respectively.

[0006] Although first-generation RET inhibitors such as vandetanib and cabozantinib can inhibit RET activity at low nM concentrations, they can also effectively inhibit a variety of non-RET kinases, and their inhibitory activity on non-RET kinases is better than that on RET. Therefore, this type of drug exhibits dose-dependent off-target-related side effects in clinical trials, such as hypertension, hand-foot syndrome, and proteinuria associated with VEGFR inhibition; rash associated with BRAF inhibition; hypopigmentation associated with KIT inhibition; diarrhea associated with EGFR inhibition, etc. The incidence of reduced doses due to dose tolerance issues for this type of drug is 23%-79%, and the incidence of treatment discontinuation is 6%-21%. In addition, when the first-generation RET inhibitors are used to treat RET-driven NSCLC, there are still problems with low overall response rate and short median progression-free survival, and the benefits of patients are far less than those of NSCLC patients with EGFR mutations, ALK and ROS1 gene fusions, etc. Like other targeted drugs, the emergence of drug-resistant mutations greatly reduces the efficacy of first-generation RET inhibitors, leading to rapid progression of cancer. Mutations in the RET gatekeeper (such as V804L and V804M) are the most important drug-resistant mutations. The mutation of Val to Leu or Met with a larger side chain increases the steric hindrance of the hydrophobic fragment of the RET inhibitor extending into the hydrophobic pocket behind the ATP binding site, reducing the affinity with the inhibitor, thus leading to the generation of drug resistance. Another major type of drug-resistant mutation is the solvent-front mutation G810R and G810A. This type of mutation is similar to ALKG1202R, ROS1G2032R, NTRK1G595R and NTRK3G623R. The mutation of Gl810 in the solvent region of RET is a larger amino acid residue, which produces a steric hindrance with the solvent region fragment of the drug and reduces affinity.

[0007] Therefore, the clinical use of first-generation RET inhibitors is subject to certain restrictions. However, no second-generation RET inhibitors with high selectivity and effectiveness against drug-resistant mutations have been approved for marketing, so there is still a need to develop excellent second-generation RET inhibitors with high selectivity and effectiveness against drug-resistant mutations. Summary of the invention

[0008] On the one hand, the present application provides a compound represented by formula (I), a stereoisomer thereof and a pharmaceutically acceptable salt thereof,

[0009]

[0010] in,

[0011] U, V and W are each independently selected from CH or N;

[0012] Ring B is selected from a 4- to 6-membered monocyclic ring, a 5- to 8-membered monoheterocyclic ring or a 6- to 10-membered bridged heterocyclic ring, wherein the monoheterocyclic ring and the bridged heterocyclic ring contain at least one N atom;

[0013] R 1 , R 7 Each is independently selected from H, cyano, hydroxyl, amino, halogen, C 1-6 Alkyl or C 1-4 Haloalkyl;

[0014] R 2 Selected from H, cyano, hydroxyl, amino, COOH, nitro, halogen, C 1-6 Alkyl or C 1-4 Haloalkyl;

[0015] Every R 3 are independently selected from cyano, halogen, C 1-6 Alkyl, C 1-4 Haloalkyl or C 1-6 Alkoxy;

[0016] R 4 , R 5 are each independently selected from H, halogen or C 1-6 Alkyl, or R 4 , R 5 Together with the carbon atom connected thereto, a 3-5 membered saturated monocyclic ring is formed, wherein the C 1-6 The alkyl group and the 3-5 membered saturated monocyclic ring may be optionally substituted by one, two or three substituents selected from halogen, hydroxyl, cyano or amino;

[0017] R 6 Selected from H, halogen, cyano, amino, hydroxyl, COOH, C 1-6 Alkyl or C 1-4 Haloalkyl;

[0018] n is 0, 1 or 2.

[0019] In some embodiments, at least one of U, V and W is selected from N.

[0020] In some embodiments, at most 2 of U, V, and W are selected from N.

[0021] In some embodiments, W is selected from CH.

[0022] In some embodiments, W is selected from CH, and at least one of U and V is selected from N.

[0023] In some embodiments, W is selected from CH, and U and V are both selected from N.

[0024] In some embodiments, W is selected from CH, V is selected from CH, and U is selected from N.

[0025] In some embodiments, R 1 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0026] In some embodiments, R 1 is selected from H, halogen, cyano, methyl or ethyl.

[0027] In some embodiments, R 1 is selected from H, halogen or methyl.

[0028] In some embodiments, R 1 Selected from H.

[0029] In some embodiments, R 7 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0030] In some embodiments, R 7 Selected from H, halogen, cyano or C 1-3 alkyl.

[0031] In some embodiments, R 7 is selected from H, halogen, cyano or methyl.

[0032] In some embodiments, R 7 Selected from H, F, cyano or methyl.

[0033] In some embodiments, R 7 Selected from cyano or methyl.

[0034] In some embodiments, R 7 Selected from cyano.

[0035] In some embodiments, R 1 Selected from H, R 7 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0036] In some embodiments, R 1 Selected from H, R 7 Selected from H, halogen, cyano or C 1-3 alkyl.

[0037] In some embodiments, R 1 Selected from H, R 7 Selected from H, F, cyano or methyl.

[0038] In some embodiments, R1 Selected from H, R 7 Selected from methyl.

[0039] In some embodiments, R 1 Selected from H, R 7 Selected from cyano.

[0040] In some embodiments, R 2 Selected from H, cyano, halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0041] In some embodiments, R 2 is selected from H, cyano, halogen, methyl, ethyl, difluoromethyl or trifluoromethyl.

[0042] In some embodiments, R 2 is selected from halogen, methyl, ethyl, difluoromethyl or trifluoromethyl.

[0043] In some embodiments, R 2 Selected from methyl or trifluoromethyl.

[0044] In some embodiments, R 2 Selected from methyl.

[0045] In some embodiments, each R 3 are independently selected from cyano, halogen, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy.

[0046] In some embodiments, each R 3 Each independently selected from C 1-3 Alkyl or C 1-3 Alkoxy.

[0047] In some embodiments, each R 3 Each is independently selected from methyl, ethyl, methoxy or ethoxy.

[0048] In some embodiments, each R 3 Each is independently selected from methyl or methoxy.

[0049] In some embodiments, each R 3 are each independently selected from methyl.

[0050] In some embodiments, n is 0 or 1.

[0051] In some embodiments, n is 0.

[0052] In some embodiments, R 4, R 5 are each independently selected from H, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0053] In some embodiments, R 4 , R 5 Each independently selected from H or C 1-3 Alkyl, the C 1-3 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0054] In some embodiments, R 4 , R 5 Each is independently selected from H, methyl, ethyl, propyl or isopropyl.

[0055] In some embodiments, R 4 , R 5 Each is independently selected from H or methyl.

[0056] In some embodiments, R 4 Selected from H, R 5 Selected from methyl.

[0057] In some embodiments, R 4 Selected from methyl, R 5 Selected from H.

[0058] In some embodiments, R 4 , R 5 Together with the carbon atom to which it is connected, it forms a cyclopropane ring, a cyclobutane ring or a cyclopentane ring, and the cyclopropane ring, the cyclobutane ring or the cyclopentane ring may be optionally substituted by one, two or three substituents selected from halogen, hydroxyl, cyano or amino.

[0059] In some embodiments, R 4 , R 5 Together with the carbon atom to which it is attached, it forms a cyclopropane ring.

[0060] In some embodiments, R 4 , R 5 Different from R 4 and R 5 The connected carbon atoms are chiral carbon atoms.

[0061] In some embodiments, R 4 , R 5 Different from R 4 and R 5 The connected carbon atoms are chiral carbon atoms, and their chiral configuration is S type.

[0062] In some embodiments, R 6 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0063] In some embodiments, R 6 Selected from halogen or C 1-3 alkyl.

[0064] In some embodiments, R 6 is selected from fluorine, chlorine, bromine or iodine.

[0065] In some embodiments, R 6 Selected from fluorine.

[0066] In some embodiments, ring B is selected from a 5- to 6-membered monocyclic ring, a 5- to 6-membered monocyclic heterocyclic ring, or a 6- to 10-membered bridged heterocyclic ring, wherein the monocyclic heterocyclic ring and the bridged heterocyclic ring contain at least one N atom.

[0067] In some embodiments, Ring B is selected from a 5-membered monocyclic ring, a 6-membered monocyclic ring, a 5-membered monoheterocyclic ring, a 6-membered monoheterocyclic ring, a 7-membered bridged heterocyclic ring, or an 8-membered bridged heterocyclic ring, wherein the monoheterocyclic ring and the bridged heterocyclic ring contain at least 1 N atom.

[0068] In some embodiments, Ring B is selected from a 5-membered monocyclic ring, a 6-membered monocyclic ring, a 5-membered monocyclic heterocyclic ring containing 1-2 N atoms, a 6-membered monocyclic heterocyclic ring containing 1-2 N atoms, a 7-membered bridged heterocyclic ring containing 1-2 N atoms, or an 8-membered bridged heterocyclic ring containing 1-2 N atoms.

[0069] In some embodiments, Ring B is selected from a 6-membered monocyclic ring, a 5-membered monocyclic heterocyclic ring containing 1-2 N atoms, a 6-membered monocyclic heterocyclic ring containing 1-2 N atoms, or an 8-membered bridged heterocyclic ring containing 1-2 N atoms.

[0070] In some embodiments, Ring B is selected from

[0071] In some embodiments, Ring B is selected from

[0072] In some embodiments, Ring B is selected from

[0073] In some embodiments, Ring B is selected from

[0074] In some embodiments, Ring B is selected from

[0075] In some embodiments, Ring B is selected from

[0076] In some embodiments, Ring B is selected from

[0077] In some embodiments, Ring B is selected from

[0078] In some embodiments, Ring B is selected from

[0079] In some embodiments, Ring B is selected from

[0080] In some embodiments, the structural unit Selected from

[0081] In some embodiments, the structural unit Selected from

[0082] In some embodiments, the structural unit Selected from

[0083] In some embodiments, the structural unit Selected from

[0084] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (II),

[0085]

[0086] Among them, U, V, ring B, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and n are as described for the compound of formula (I).

[0087] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (III),

[0088]

[0089] Among them, U, V, ring B, R 2 , R 3 , R 6 , R 7 and n are as described for the compound of formula (I).

[0090] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (III-1),

[0091]

[0092] Among them, U, V, ring B, R 2 , R 3 , R 6 , R 7 and n are as described for the compound of formula (I).

[0093] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (IV-1),

[0094]

[0095] Among them, U, V, ring B, R 2 , R 3 , R 7 and n are as described for the compound of formula (I).

[0096] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (V-1),

[0097]

[0098] Among them, ring B, R 2 , R 3 , R 7 and n are as described for the compound of formula (I).

[0099] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (VI-1),

[0100]

[0101] Among them, ring B, R 2 , R 3 , R 7 and n are as described for the compound of formula (I).

[0102] In some embodiments, the compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (VII-1),

[0103]

[0104] Among them, U, V, R 2, R 3 , R 7 and n are as described for the compound of formula (I).

[0105] On the other hand, the present application also provides a compound represented by formula (A), a stereoisomer thereof and a pharmaceutically acceptable salt thereof,

[0106]

[0107] in,

[0108] U 1 、V 1 , W 1 are each independently selected from CH or N;

[0109] P and Q are each independently selected from C(R 11 ) or N;

[0110] Ring B 1 is selected from a 4- to 6-membered monocyclic ring, a 5- to 8-membered monocyclic heterocyclic ring or a 6- to 10-membered bridged heterocyclic ring, wherein the monocyclic heterocyclic ring and the bridged heterocyclic ring contain at least one N atom;

[0111] R 11 Selected from H, cyano, hydroxyl, amino, halogen, C 1-6 Alkyl or C 1-4 Haloalkyl;

[0112] R 21 Selected from H, cyano, hydroxyl, amino, COOH, nitro, halogen, C 1-6 Alkyl or C 1-4 Haloalkyl;

[0113] Every R 31 are independently selected from cyano, halogen, C 1-6 Alkyl, C 1-4 Haloalkyl or C 1-6 Alkoxy;

[0114] R 41 , R 51 are each independently selected from H, halogen or C 1-6 Alkyl, or R 41 , R 51 Together with the carbon atom connected thereto, a 3-5 membered saturated monocyclic ring is formed, wherein the C 1-6 The alkyl group or the 3-5 membered saturated monocyclic ring may be optionally substituted by one, two or three substituents selected from halogen, hydroxyl, cyano or amino;

[0115] R 61 Selected from H, halogen, cyano, amino, hydroxyl, COOH, C 1-6 Alkyl or C 1-4 Haloalkyl;

[0116] m is 0, 1 or 2.

[0117] In some embodiments, U 1 、V 1 and W 1 At least one of them is selected from N.

[0118] In some embodiments, U 1 、V 1 and W 1 At most 2 of them are selected from N.

[0119] In some embodiments, W 1 Selected from CH.

[0120] In some embodiments, W 1 Selected from CH, U 1 and V 1 At least one of them is selected from N.

[0121] In some embodiments, W 1 Selected from CH, U 1 and V 1 All are selected from N.

[0122] In some embodiments, W 1 Selected from CH, V 1 Selected from CH, U 1 Selected from N.

[0123] In some embodiments, R 11 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0124] In some embodiments, R 11 is selected from H and halogen.

[0125] In some embodiments, R 11 Selected from H and F.

[0126] In some embodiments, P is N, Q is C(R 11 ).

[0127] In some embodiments, P is C(R 11 ), Q is N or C (R 11 ).

[0128] In some embodiments, P is N and Q is CH.

[0129] In some embodiments, P is C(F) and Q is CH.

[0130] In some embodiments, P is CH and Q is N.

[0131] In some embodiments, R 21 Selected from H, cyano, halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0132] In some embodiments, R 21 Selected from methyl.

[0133] In some embodiments, each R 31 Each independently selected from C 1-3 Alkyl or C 1-3 Alkoxy.

[0134] In some embodiments, each R 31 Each is independently selected from methoxy or ethoxy.

[0135] In some embodiments, each R 31 are each independently selected from methoxy.

[0136] In some embodiments, m is 0 or 1.

[0137] In some embodiments, m is 0.

[0138] In some embodiments, R 41 , R 51 are each independently selected from H, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0139] In some embodiments, R 41 , R 51 Each independently selected from H or C 1-3 Alkyl, the C 1-3 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0140] In some embodiments, R 41 , R 51 Each is independently selected from H, methyl, ethyl, propyl or isopropyl.

[0141] In some embodiments, R 41 , R 51 Each is independently selected from H or methyl.

[0142] In some embodiments, R 41 Selected from H, R 51 Selected from methyl.

[0143] In some embodiments, R 41 Selected from methyl, R 51 Selected from H.

[0144] In some embodiments, R 41 , R 51 Together with the carbon atom to which it is attached, it forms a cyclopropane ring.

[0145] In some embodiments, R 41 , R 51 Different from R 41 and R 51 The connected carbon atoms are chiral carbon atoms.

[0146] In some embodiments, R 41 , R 51 Different from R 41 and R 51 The connected carbon atoms are chiral carbon atoms, and their chiral configuration is S type.

[0147] In some embodiments, R 61 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

[0148] In some embodiments, R 61 Selected from halogen or C 1-3 alkyl.

[0149] In some embodiments, R 61 is selected from fluorine, chlorine, bromine or iodine.

[0150] In some embodiments, R 61 Selected from fluorine.

[0151] In some embodiments, Ring B 1 It is selected from a 5- to 6-membered monocyclic ring or a 6- to 10-membered bridged heterocyclic ring, wherein the bridged heterocyclic ring contains at least one N atom.

[0152] In some embodiments, Ring B 1 It is selected from a 5-membered monocyclic ring, a 6-membered monocyclic ring, a 7-membered bridged heterocyclic ring or an 8-membered bridged heterocyclic ring, wherein the bridged heterocyclic ring contains at least one N atom.

[0153] In some embodiments, Ring B 1 It is selected from a 5-membered monocyclic ring, a 6-membered monocyclic ring, a 7-membered bridged heterocyclic ring containing 1-2 N atoms, or an 8-membered bridged heterocyclic ring containing 1-2 N atoms.

[0154] In some embodiments, Ring B 1 It is selected from a 6-membered monocyclic ring or an 8-membered bridged heterocyclic ring containing 1-2 N atoms.

[0155] In some embodiments, Ring B 1 Selected from

[0156] In some embodiments, Ring B 1 Selected from

[0157] In some embodiments, Ring B 1 Selected from

[0158] In some embodiments, Ring B 1 Selected from

[0159] In some embodiments, Ring B 1 Selected from

[0160] In some embodiments, Ring B 1 Selected from

[0161] In some embodiments, the structural unit Selected from

[0162] In some embodiments, the structural unit Selected from

[0163] In some embodiments, the structural unit Selected from

[0164] In some embodiments, the compound represented by formula (A), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (A-1),

[0165]

[0166] Among them, U 1 、V 1 , P, Q, Ring B 1 , R 21 , R 31 and m are as described for the compound of formula (A).

[0167] In some embodiments, the compound represented by formula (A), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (A-2),

[0168]

[0169] Among them, U 1 、V1 、Ring B 1 , R 21 , R 31 and m are as described for the compound of formula (A).

[0170] In some embodiments, the compound represented by formula (A), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (A-3),

[0171]

[0172] Among them, U 1 、V 1 、Ring B 1 , R 11 , R 21 , R 31 and m are as described for the compound of formula (A).

[0173] In some embodiments, the compound represented by formula (A), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (A-4),

[0174]

[0175] Among them, U 1 、V 1 、Ring B 1 , R 21 , R 31 and m are as described for the compound of formula (A).

[0176] In some embodiments, the compound represented by formula (A), its stereoisomers and pharmaceutically acceptable salts thereof are selected from the compound represented by formula (A-5),

[0177]

[0178] Among them, U 1 、V 1 , P, Q, R 21 , R 31 and m are as described for the compound of formula (A).

[0179] In some embodiments, the compound of formula (I) of the present application is selected from the following compounds, their stereoisomers and pharmaceutically acceptable salts thereof:

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186] In some embodiments, the compound of formula (A) of the present application is selected from the following compounds, their stereoisomers and pharmaceutically acceptable salts thereof:

[0187]

[0188] On the other hand, the present application relates to a pharmaceutical composition comprising the compound of formula (I) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof.

[0189] In some embodiments, the pharmaceutical composition of the present application comprises a therapeutically effective amount of the compound of formula (I) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof.

[0190] In another aspect, the present application relates to a pharmaceutical composition comprising the compound of formula (A) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof.

[0191] In some embodiments, the pharmaceutical composition of the present application comprises a therapeutically effective amount of the compound of formula (A) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof.

[0192] In some embodiments, the pharmaceutical composition of the present application further comprises a pharmaceutically acceptable excipient.

[0193] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0194] Typical routes of administration of the compounds of the present application or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0195] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.

[0196] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be prepared by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions, etc., for oral administration to patients.

[0197] Solid oral compositions can be prepared by conventional mixing, filling or tableting methods. For example, they can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into particles to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, adhesives, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, etc.

[0198] On the other hand, the present application relates to a method for treating a disease mediated by abnormal RET activity in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I), a compound of formula (A), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, to a mammal, preferably a human, in need of such treatment.

[0199] In all administration methods of the compound of formula (I), compound of formula (A), stereoisomers thereof or pharmaceutically acceptable salts thereof of the present application, the daily dosage is 0.01 to 100 mg / kg body weight, preferably 0.05 to 50 mg / kg body weight, more preferably 0.1 to 5 mg / kg body weight, in the form of a single or divided dose.

[0200] On the other hand, the present application relates to the use of a compound of formula (I), a compound of formula (A), stereoisomers thereof and pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof in the preparation of a drug for preventing or treating a disease mediated by abnormal RET activity.

[0201] On the other hand, the present application relates to the use of a compound of formula (I), a compound of formula (A), stereoisomers thereof and pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof in preventing or treating diseases mediated by abnormal RET activity.

[0202] On the other hand, the present application relates to compounds of formula (I), compounds of formula (A), stereoisomers thereof and pharmaceutically acceptable salts thereof for preventing or treating diseases mediated by abnormal RET activity.

[0203] The diseases mediated by abnormal RET activity described in the present application include cancer.

[0204] In some embodiments, the cancer described in the present application is selected from papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), pheochromocytoma (PC), pancreatic cancer, multiple endocrine neoplasia (MEN2A and MEN2B), breast cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, blood tumors, colorectal cancer, ovarian cancer, cervical cancer, gastric cancer, prostate cancer, salivary gland cancer.

[0205] The compounds of the present application have good RET kinase and RET (V804M) kinase inhibitory activity, tumor cell inhibitory activity and good in vivo pharmacokinetic properties.

[0206] definition

[0207] Unless otherwise specified, the following terms used in this application have the following meanings. A particular term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.

[0208] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0209] The term "pharmaceutically acceptable salt" refers to salts of compounds of the present application, prepared from compounds with specific substituents found in the present application and relatively non-toxic acids or bases. When the compounds of the present application contain relatively acidic functional groups, base addition salts can be obtained by contacting a neutral form of such compounds with a suitable base. When the compounds of the present application contain relatively basic functional groups, acid addition salts can be obtained by contacting a neutral form of such compounds with a suitable acid. Certain specific compounds of the present application contain basic and acidic functional groups, and thus can be converted into either base or acid addition salts.

[0210] Certain compounds of the present application may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are all included within the scope of the present application.

[0211] The compounds of the present application may exist in specific geometric or stereoisomeric forms. The present application contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present application. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present application. For example, the compound structure contains are cis- and trans-isomers; for example, There are (R)- and (S)-enantiomers.

[0212] Optically active (R)- and (S)-isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present application is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary groups are cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is usually accomplished by using chromatography, which uses a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., the formation of a carbamate from an amine).

[0213] The compounds of the present application may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium ( 2 H), tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C) All isotopic variations of the compounds of the present application, whether radioactive or not, are included within the scope of the present application.

[0214] The term "pharmaceutically acceptable excipients" refers to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0215] The term "treatment" means administering the compound or formulation described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0216] (i) inhibiting a disease or disease state, i.e. arresting its development;

[0217] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.

[0218] The term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a drug or pharmaceutical agent to achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.

[0219] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating a target disorder, disease, or condition.

[0220] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be construed in an open and non-exclusive sense, ie, "including but not limited to".

[0221] The term "optional" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes the occurrence of the event or situation and the non-occurrence of the event or situation. For example, an ethyl group is "optionally" substituted with a halogen, meaning that the ethyl group may be unsubstituted (CH2CH3), monosubstituted (such as CH2CH2F), polysubstituted (such as CHFCH2F, CH2CHF2, etc.) or fully substituted (CF2CF3). It will be appreciated by those skilled in the art that for any group comprising one or more substituents, no substitution or substitution pattern that is sterically impossible to exist and / or cannot be synthesized will be introduced.

[0222] The C used in this paper m-n means that there are mn carbon atoms in the part. For example, "C 3-10 "Cycloalkyl" means that the cycloalkyl group has 3 to 10 carbon atoms.

[0223] The numerical ranges herein refer to each integer in the given range. For example, "C 1-10 ” means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.

[0224] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is a keto group (i.e., =O) (also known as an oxo group), it means that two hydrogen atoms are replaced, and keto substitution does not occur on an aromatic group.

[0225] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, and each occurrence of R is an independent choice. In addition, combinations of substituents and / or variants thereof are permitted only if such combinations result in stable compounds.

[0226] When a substituent's bond can cross-link to two atoms on a ring, the substituent can be bonded to any atom on the ring. When a substituent is listed without indicating the atom through which it is bonded to the compound included but not specifically mentioned in the chemical formula, the substituent can be bonded through any atom. Combinations of substituents and / or their variants are permitted only if such combinations result in stable compounds. For example, the structural unit It means that it can be substituted at any position on the cyclohexyl group or cyclohexadiene. For example, the structural unit express

[0227] The term "cyano" refers to -CN.

[0228] The term "amino" refers to -NH2.

[0229] The term "hydroxy" refers to -OH.

[0230] The term "nitro" refers to -NO2.

[0231] The term "alkyl" refers to a straight or branched saturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc. The specific alkyl group includes all isomeric forms thereof, such as propyl includes -CH2CH2CH3, -CH(CH3)2, and butyl includes -CH2CH2CH2CH3, -CH(CH3)(CH2CH3), -C(CH3)3, -CH2CH(CH3)2. The term "C 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms. The term "C 1-4 "Alkyl" refers to an alkyl group having 1 to 4 carbon atoms. The term "C 1-3 "Alkyl" refers to an alkyl group having 1 to 3 carbon atoms.1-8 Alkyl", "C 1-6 Alkyl" or "C 1-3 The "alkyl" group may be unsubstituted or substituted by one or more substituents selected from hydroxy, halogen or amino.

[0232] The term "halo" or "halogen" by itself or as part of another substituent refers to a fluorine, chlorine, bromine or iodine atom. In addition, the term "haloalkyl" is intended to include monohaloalkyl and polyhaloalkyl; for example, the term "haloC1-3alkyl" is intended to include but is not limited to trifluoromethyl, 2,2,2-trifluoroethyl and 3-bromopropyl, etc. Examples of haloalkyl include but are not limited to: trifluoromethyl, trichloromethyl, pentafluoroethyl and pentachloroethyl.

[0233] The term "alkoxy" refers to an alkyl group as defined above having the specified number of carbon atoms attached through an oxygen bridge. 1-6 Alkoxy groups include C1, C2, C3, C4, C5 and C6 alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy and S-pentoxy.

[0234] Unless otherwise specified, the term "hetero" means a heteroatom or heteroatom group (i.e., an atom group containing heteroatoms), including atoms other than carbon (C) and hydrogen (H) and atom groups containing these heteroatoms, for example, including oxygen (O), nitrogen (N), sulfur (S), silicon (Si), germanium (Ge), aluminum (Al), boron (B), -O-, -S-, =O, =S, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, and -C(=O)N(H)-, -N(H)-, -C(=NH)-, -S(=O)2N(H)- or -S(=O)N(H)-.

[0235] Unless otherwise specified, the term "monocyclic ring" means a saturated or partially saturated monocyclic cyclic hydrocarbon, the monocyclic ring containing 3 to 12 carbon atoms, preferably 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic rings include cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclopentene ring, cyclohexyl ring, cyclohexene ring, cyclohexadiene ring, cycloheptyl ring, cycloheptatriene ring, cyclooctane ring, etc.

[0236] The term "monocyclic heterocycle" refers to a monocyclic ring having 3 to 12 ring atoms, wherein 1 or 2 ring atoms are selected from N, O, S(O) n (where n is 0, 1 or 2) with the remaining ring atoms being C. Such rings may be saturated or unsaturated (e.g., have one or more double bonds), but do not have a completely conjugated π-electron system. Examples of 3-membered saturated monocyclic heterocycles include, but are not limited to Examples of 4-membered saturated monocyclic heterocycles include, but are not limited to Examples of 5-membered saturated monocyclic heterocycles include, but are not limited to Examples of 6-membered saturated monocyclic heterocycles include, but are not limited to Examples of 7-membered saturated monocyclic heterocycles include, but are not limited to Examples of 5-membered unsaturated monocyclic heterocycles include, but are not limited to Examples of 6-membered unsaturated monocyclic heterocycles include, but are not limited to

[0237] The term "bridged heterocycle" refers to a polycyclic ring with 5 to 14 members, two rings sharing two or more atoms, which may contain one or more double bonds, but none of the rings has a completely conjugated π electron system, wherein one or more ring atoms are selected from N, O, S(O) n (where n is 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably, it is 6 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocycles, preferably bicyclic or tricyclic, and more preferably bicyclic. Non-limiting examples of bridged heterocycles include:

[0238] The compounds of the present application can be prepared by a variety of synthesis methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.

[0239] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.

[0240] An important consideration in synthetic route planning in the art is to select a suitable protecting group for a reactive functional group (such as the amino group in this application). For example, reference may be made to Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc. All references cited in this application are incorporated herein in their entirety.

[0241] The compound of the general formula (I) of the present application can be prepared by a person skilled in the art of organic synthesis through the following route:

[0242] Solution 1:

[0243]

[0244] Option 2:

[0245]

[0246] Among them, ring B, R 1 , R 2 , R 3 , R 6 , R 7 and n are as described for the compound of formula (I).

[0247] This application uses the following abbreviations:

[0248] “Room temperature” refers to 20-30°C; “DMSO” refers to dimethyl sulfoxide; “t-BuOK” refers to potassium tert-butoxide; “K3PO4” refers to potassium phosphate; “THF” refers to tetrahydrofuran; “DMF” refers to dimethylformamide; “TFA” refers to trifluoroacetic acid; “Et3N” refers to triethylamine; “CDI” refers to N,N'-carbonyldiimidazole; “DCM” refers to dichloromethane; “XPhos” refers to 2-dicyclohexylphosphine-2,4- ,6-triisopropylbiphenyl; "Pd3(dba)2" refers to tris(dibenzylideneacetone)dipalladium; "HEPES" refers to N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; "MgCl2" refers to magnesium chloride; "DTT" refers to dithiothreitol; "EGTA" refers to ethylene glycol-bis-(2-aminoethyl ether)tetraacetic acid; "EDTA" refers to ethylenediaminetetraacetic acid; "FBS" refers to fetal bovine serum; "CCK-8" refers to cell counting kit-8 reagent.

[0249] Specific embodiment

[0250] The present application is described in detail below by way of examples, but this does not mean any adverse limitation to the present application. The present disclosure has been described in detail herein, and its specific embodiments are also disclosed therein. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present disclosure without departing from the spirit and scope of the present application.

[0251] Example 1: Preparation of Compound 1

[0252]

[0253] Step A: Preparation of Compound 1-1

[0254] To a 250mL single-mouth bottle, add 2,4-dichloro-6-methylpyrimidine (8.57g), 5-methyl-2-aminothiazole (5g) and tetrahydrofuran (30mL) in sequence. Under nitrogen protection, cool the reaction system to 0°C and add potassium tert-butoxide (14.74g) in batches. After the addition is complete, transfer the reaction to room temperature and stir overnight. Stop stirring, remove the solvent under reduced pressure by rotary evaporator, and add 100mL of water to the residue. After stirring at room temperature for 1h, filter, and remove the water from the filter cake by rotary evaporator under reduced pressure. Add dichloromethane (100mL) to the residue, stir at room temperature for 1h, filter, wash the filter cake with 10mL×3 dichloromethane, collect the filter cake, and remove the organic solvent under reduced pressure by rotary evaporator to obtain 8g of compound 1-1.

[0255] MS (ESI, [M+H] + )m / z:241.1.

[0256] Step B: Preparation of Compound 1-2

[0257] Compound 1-1 (0.5 g), (S)-1-N-Boc-2-methylpiperazine (0.499 g) and N,N-dimethylformamide (10 mL) prepared in step A were added to a 20 mL sealed tube in sequence. After stirring for 1 min, the mixture was placed in a microwave reactor and heated to 140°C at 50 W for 2 h. After the reaction was completed, 100 mL of ethyl acetate and 100 mL of water were added to the reaction solution. The organic phase was separated, washed with saturated brine (3×25 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. 0.29 g of compound 1-2 was obtained by column chromatography.

[0258] MS (ESI, [M+H] + )m / z:405.3.

[0259] Step C: Preparation of Compound 1-3

[0260] In a 50 mL round-bottom flask, compound 1-2 (0.29 g) prepared in step B, dichloromethane (10 mL) and trifluoroacetic acid (4 mL) were added in sequence and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to obtain 0.8 g of compound 1-3, which could be directly used in the next step.

[0261] MS (ESI, [M+H] + )m / z:305.1.

[0262] Step D: Preparation of Compound 1

[0263] Under nitrogen protection, N,N'-carbonyldiimidazole (202 mg) was added to a tetrahydrofuran solution of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine dihydrochloride (174 mg) and N,N-diisopropylethylamine (403 mg), and the mixture was stirred at room temperature for 0.5 h. Compound 1-3 (190 mg as free base) prepared in step C and a tetrahydrofuran solution of N,N-diisopropylethylamine (403 mg) were added dropwise to the reaction system. The reaction was allowed to react overnight at room temperature. After the reaction was completed, the reaction solution was concentrated, and the crude product was purified by column chromatography to obtain 50 mg of compound 1.

[0264] 1 H NMR(500MHz,DMSO-d6)δ11.16(s,1H),8.68(d,J=4.5Hz,1H),8.41(s,1H),7.96(d,J=10.4Hz, 1H),7.92(d,J=4.2Hz,1H),7.87(d,J=8.5Hz,1H),7.08(s,1H),6.95(d,J=7.6Hz,1H),6.06(s ,1H),4.95-4.97(m,1H),4.62-4.65(m,2H),4.37(s,1H),3.87-3.90(m,1H),3.15-3.17(m,1H ),2.95-3.04(m,2H),2.35(s,3H),2.18(s,3H),1.44(d,J=7.0Hz,3H),1.05(d,J=6.4Hz,3H).

[0265] MS (ESI, [M+H] + )m / z:537.3.

[0266] Example 2: Preparation of Compound 2

[0267]

[0268] The synthesis method is as in Example 1.

[0269] 1H NMR(500MHz,DMSO-d6)δ11.14(s,1H),8.67(d,J=4.5Hz,1H),8.41(s,1H),7.94-7.96(m,1H),7.91 (d,J=4.2Hz,1H),7.87(d,J=8.5Hz,1H),7.08(s,1H),6.94(d,J=7.4Hz,1H),6.06(s,1H),4.92-4. 98(m,1H),4.64(d,J=11.5Hz,1H),4.56-4.59(m,1H),4.35(s,1H),3.89-3.91(m,1H),3.15-3.17( m,1H),2.94-3.04(m,2H),2.35(s,3H),2.18(s,3H),1.44(d,J=7.1Hz,3H),1.05(d,J=6.6Hz,3H).

[0270] MS (ESI, [M+H] + )m / z:537.23.

[0271] Example 3: Preparation of Compound 3

[0272]

[0273] The synthesis method is as in Example 1.

[0274] 1 H NMR (500MHz, DMSO-d6) δ11.17(s,1H),8.68(d,J=4.5Hz,1H),8.42(s,1H),7.97(dd,J=8.5,2.0Hz,1H),7.92(d,J=4.2Hz,1H),7.88(d,J=8.5Hz,1H ),7.08(s,1H),7.04(d,J=7.5Hz,1H),6.08(s,1H),4.93-4.96(m,1H),3. 80(s,4H),3.45(s,4H),2.35(s,3H),2.18(s,3H),1.44(d,J=7.1Hz,3H).

[0275] MS (ESI, [M+H] + )m / z:523.2.

[0276] Example 4: Preparation of Compound 4

[0277]

[0278] Step A: Preparation of Compound 4-1

[0279] The synthesis method is similar to that of step B in Example 1.

[0280] Step B: Preparation of compound 4-2

[0281] 5-methyl-2-aminothiazole (65 mg), 1,4-dioxane (10 mL), compound 4-1 (144 mg) prepared in step A, potassium phosphate (161 mg) and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl (36.2 mg) were added to a 20 mL microwave tube in sequence and stirred evenly. Purge with nitrogen for 2 min, then add tris(dibenzylideneacetone)dipalladium (34.8 mg) to the tube, and seal the microwave tube after nitrogen purge for 2 min. Set the power of the microwave reactor to 200 W, raise the temperature to 100 ° C and react for 2 h. After the reaction is completed, the reaction solution is concentrated, and the crude product is purified by column chromatography to obtain 174 mg of compound 4-2.

[0282] MS (ESI, [M+H] + )m / z:458.2.

[0283] Step C: Preparation of Compound 4-3

[0284] The synthesis method is similar to that of step C in Example 1.

[0285] Step D: Preparation of Compound 4

[0286] The synthesis method is similar to that of step D in Example 1.

[0287] 1 H NMR(500MHz,DMSO-d6)δ11.12(s,1H),8.67(d,J=4.3Hz,1H),8.41(s,1H),7.86 -7.97(m,3H),7.07(s,1H),6.97(d,J=7.3Hz,1H),6.49(s,2H),4.93-4.98(m,1 H),4.32-4.34(m,3H),3.90-3.93(m,1H),3.23-3.25(m,1H),3.12-3.16(m,1H) ,3.02-3.06(m,1H),2.35(s,3H),1.45(d,J=7.0Hz,3H),1.10(d,J=6.3Hz,3H).

[0288] HRMS (ESI, [M+H] + )m / z:590.2067.

[0289] Example 5: Preparation of Compound 5

[0290]

[0291] The synthesis method is as in Example 4.

[0292] 1 H NMR (500MHz, DMSO-d6) δ10.67 (s, 1H), 8.67 (d, J = 4.5Hz, 1H), 8.41 (s, 1H), 7.86-7. 97(m,3H),6.99(s,1H),6.94(d,J=7.7Hz,1H),6.11(d,J=4.6Hz,2H),4.94-4.99(m, 1H),4.36(s,1H),4.18-4.27(m,2H),3.86-3.89(m,1H),3.08-3.14(m,2H),2.85-2 .90(m,1H),2.32(s,3H),2.16(s,3H),1.45(d,J=7.1Hz,3H),1.11(d,J=6.5Hz,3H).

[0293] HRMS (ESI, [M+H] + )m / z:536.2344.

[0294] Example 6: Preparation of Compound 6-a and Compound 6-b

[0295]

[0296] Step A: Preparation of Compound 6-1

[0297] Compound 1-1 (2 g), 1-methoxy-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)cyclohexane-3-ene-1-carboxylic acid methyl ester (3.69 g), tetrakis(triphenylphosphine)palladium (0.480 g), potassium carbonate (3.44 g), 1,4-dioxane (6 mL) and water (1 mL) were added to a 30 mL sealed tube in sequence, stirred for 1 min, placed in a microwave reactor, heated to 125° C. at 50 W for 2 h. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain 560 mg of compound 6-1.

[0298] MS (ESI, [M+H] + )m / z:375.2.

[0299] Step B: Preparation of compound 6-2

[0300] In a 100 mL eggplant-shaped bottle, compound 6-1 (500 mg) prepared in step A, 10% palladium hydroxide on carbon (938 mg) and methanol (5 mL) were added in sequence, hydrogen was replaced 3 times and protected, and the mixture was heated to 78°C for 48 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain 190 mg of compound 6-2.

[0301] MS (ESI, [M+H] + )m / z:377.2.

[0302] Step C: Preparation of Compound 6-3

[0303] In a 100 mL eggplant-shaped bottle, compound 6-2 (190 mg), ethanol (6 mL) and tetrahydrofuran (6 mL) prepared in step B were added in sequence, followed by sodium hydroxide (60.6 mg) and water (1 mL), and reacted at 50 ° C for 5 h under nitrogen protection. After the reaction was completed, stirring was stopped and the pH was adjusted to acidic with 1 M hydrochloric acid. The solvent was evaporated under reduced pressure by a rotary evaporator to obtain 387 mg of a product containing compound 6-3, which was directly used in the next step without purification.

[0304] MS (ESI, [M+H] + )m / z:363.2.

[0305] Step D: Preparation of Compound 6-a and Compound 6-b

[0306] Compound 6-3 (285 mg) prepared in step C, (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethane-1-amine dihydrochloride (104 mg), 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate (291 mg), N,N-diisopropylethylamine (144 mg) and N,N-dimethylformamide (10 mL) were added to a 100 mL eggplant-shaped bottle in sequence, and reacted at room temperature for 1 h under nitrogen protection. 50 mL of ethyl acetate and 10 mL of water were added to the reaction system, extracted twice with 30 mL of ethyl acetate, the organic phase was collected, and the organic phase was washed three times with saturated brine. Drying over anhydrous sodium sulfate, filtering, and purifying the filtrate by column chromatography and chiral separation to obtain 40 mg of compound 6-a and 35 mg of compound 6-b.

[0307] Compound 6-a:

[0308] 1H NMR(500MHz,Chloroform-d)δ8.31(s,2H),7.85(d,J=8.5Hz,1H),7.70(d,J=8.4Hz,1H),7.51(d,J=3.8Hz,1H),7.19(s,1H),7.05(s,1H),6.81(d,J=7.9 Hz,1H),6.55(s,1H),5.09-5.12(m,1H),3.23(s,3H),2.53-2.61(d,J=44.2 Hz,1H),2.40(s,3H),2.33(s,3H),1.77-1.97(m,8H),1.51(d,J=6.9Hz,3H).

[0309] HRMS (ESI, [M+H] + )m / z:551.2346.

[0310] Compound 6-b:

[0311] 1 H NMR(500MHz,Chloroform-d)δ8.29(s,2H),7.83(d,J=8.5Hz,1H),7.68(d,J=10.6Hz,1H),7.50(d,J=4.3Hz,1H),7.19(s,1H),7.00(s,1H),6.68(d, J=7.9Hz,1H),6.60(s,1H),5.06–5.11(m,1H),3.17(s,3H),2.66-2.69(m ,1H),2.38(s,3H),2.32(s,3H),1.90-2.14(m,8H),1.49(d,J=7.0Hz,3H).

[0312] HRMS (ESI, [M+H] + )m / z:551.2346.

[0313] Example 7: Preparation of Compound 7

[0314]

[0315] The synthesis method is as in Example 1.

[0316] 1H NMR(500MHz,DMSO-d6)δ11.17(s,1H),8.67(s,1H),8.39(s,1H),7.91(s,2H),7.86(s,1H),7.08(s,1H),6.81(s,1H),6.10(s,1H),4. 90(s,2H),4.69(s,1H),3.78(s,2H),3.18-2.89(m,2H),2.35(s,3H),2.19(s,3H),1.91(s,2H),1.74(s,2H),1.20(d,J=18.9Hz,3H).

[0317] MS (ESI, [M+H] + )m / z:549.3.

[0318] Example 8: Preparation of Compound 8

[0319]

[0320] The synthesis method is as in Example 1.

[0321] 1 H NMR (500MHz, DMSO-d6) δ11.12(s,1H),8.67(d,J=4.5Hz,1H),8.43(d,J=1.8 Hz,1H),7.99-7.95(m,1H),7.93-7.87(m,2H),7.15(d,J=7.7Hz,1H),7.08(s ,1H),6.09(s,1H),4.97(p,J=6.9Hz,1H),4.45(s,4H),3.06(s,2H),2.36(s, 3H), 2.18 (s, 3H), 1.78 (s, 2H), 1.60 (d, J = 7.1Hz, 2H), 1.46 (d, J = 7.1Hz, 3H).

[0322] MS (ESI, [M+H] + )m / z:549.3.

[0323] Example 9: Preparation of Compound 9

[0324]

[0325] The synthesis method is as in Example 1.

[0326] 1H NMR(500MHz,DMSO-d6)δ11.36(s,1H),8.67(d,J=4.5Hz,1H),8.41(d,J=2.0Hz,1H),7 .95(dd,J=8.5,2.2Hz,1H),7.90(d,J=4.2Hz,1H),7.86(d,J=8.5Hz,1H),7.42(d,J=3 .6Hz,1H),7.13(d,J=3.6Hz,1H),7.00(d,J=7.5Hz,1H),6.11(s,1H),4.93(t,J=7.2H z,1H),3.87-3.73(m,4H),3.44(t,J=5.3Hz,4H),2.19(s,3H),1.43(d,J=7.1Hz,3H).

[0327] MS (ESI, [M+H] + )m / z:509.3.

[0328] Example 10: Preparation of Compound 10

[0329]

[0330] The synthesis method is as in Example 1.

[0331] 1 H NMR (500MHz, DMSO-d6) δ11.34(s,1H),8.66(d,J=4.6Hz,1H),8.40(d,J=2.1Hz,1H),7.95(dd,J=8.5,2.2Hz,1 H),7.90(d,J=4.3Hz,1H),7.86(d,J=8.5Hz,1H),7.42(d,J=3.6Hz,1H),7.13(d,J=3.6Hz,1H),6.90(d,J=7.6 Hz,1H),6.10(s,1H),4.94(p,J=7.1Hz,1H),4.63(d,J=12.4Hz,2H),4.36(s,1H),3.87(d,J=12.6Hz,1H),3.1 8(d,J=9.6Hz,1H),3.01(dd,J=27.2,11.5Hz,2H),2.19(s,3H),1.43(d,J=7.1Hz,3H),1.04(d,J=6.6Hz,3H).

[0332] MS (ESI, [M+H] + )m / z:523.2.

[0333] Example 11: Preparation of Compound 11

[0334]

[0335] The synthesis method is as in Example 4.

[0336] 1 H NMR(500MHz,DMSO-d6)δ10.67(s,1H),8.66(d,J=4.2Hz,1H),8.41(s,1H),7.95(d,J=8 .4Hz,1H),7.91–7.82(m,2H),7.03–6.84(m,2H),6.11(s,2H),5.01–4.86(m,1H),4.33( s,1H),4.22(d,J=11.3Hz,2H),3.90(d,J=12.9Hz,1H),3.09(d,J=12.0Hz,2H),2.88(t, J=10.5Hz,1H),2.31(s,3H),2.15(s,3H),1.44(d,J=7.0Hz,3H),1.11(d,J=6.5Hz,3H).

[0337] MS (ESI, [M+H] + )m / z:536.4.

[0338] Example 12: Preparation of Compound 12

[0339]

[0340] The synthesis method is as in Example 4.

[0341] 1 H NMR (500MHz, DMSO-d6) δ10.69(s,1H),8.65(s,1H),8.37(s,1H),7.98–7.80(m,3H),6.98(s,1H),6.78(s,1H),6.11(d,J=19.1Hz,2H ),4.88(s,1H),4.64(s,2H),3.69(s,2H),3.06(d,J=12.0Hz,2H),2.31(s,3H),2.15(s,3H),1.92(s,2H),1.74(s,2H),1.40(s,3H).

[0342] MS (ESI, [M+H] + )m / z:548.3.

[0343] Example 13: Preparation of Compound 13

[0344]

[0345] The synthesis method is as in Example 4.

[0346] 1 H NMR (500MHz, DMSO-d6) δ10.67(s,1H),8.66(d,J=4.5Hz,1H),8.41(d,J=1.8Hz,1H),7.95(dd,J=8.5,2.1Hz,1H),7.92-7.83(m,2H),7.06-6. 95(m,2H),6.14(s,2H),4.94(p,J=7.0Hz,1H),3.55(d,J=5.4Hz,4H),3.48(d,J=5.1Hz,4H),2.31(s,3H),2.16(s,3H),1.44(d,J=7.1Hz,3H).

[0347] MS (ESI, [M+H] + )m / z:522.3.

[0348] Example 14: Preparation of Compound 14

[0349]

[0350] The synthesis method is as in Example 4.

[0351] 1 H NMR (500MHz, DMSO-d6) δ11.09(s,1H),8.64(d,J=4.3Hz,1H),8.41(s,1H),7.95(d,J=8. 4Hz,1H),7.87(dd,J=11.5,6.3Hz,2H),7.18(d,J=7.6Hz,1H),7.05(s,1H),6.51(s,1H) ,6.38(s,1H),4.95(p,J=6.6Hz,1H),4.49(d,J=14.2Hz,2H),4.19-3.99(m,2H),3.09(d ,J=12.0Hz,2H),2.34(s,3H),1.81(s,2H),1.68(d,J=8.0Hz,2H),1.44(d,J=6.9Hz,3H).

[0352] MS (ESI, [M+H] + )m / z:602.3.

[0353] Example 15: Preparation of Compound 15

[0354]

[0355] The synthesis method is as in Example 4.

[0356] 1H NMR(500MHz,DMSO-d6)δ10.63(s,1H),8.65(d,J=4.4Hz,1H),8.41(d,J=2.0Hz,1H),7.95 (dd,J=8.5,2.2Hz,1H),7.92-7.82(m,2H),7.15(d,J=7.7Hz,1H),7.02-6.93(m,1H),6.12 (s,1H),6.01(s,1H),4.95(p,J=7.0Hz,1H),4.47(d,J=13.7Hz,2H),3.99(d,J=10.2Hz,2 H), 2.99 (d, J = 13.1Hz, 2H), 2.54 (s, 4H), 2.31 (s, 3H), 2.14 (s, 3H), 1.44 (d, J = 7.1Hz, 3H).

[0357] MS (ESI, [M+H] + )m / z:548.3.

[0358] Example 16: Preparation of Compound 16

[0359]

[0360] Step A: Preparation of Compound 16-1

[0361] Compound 12-1 (1.00 g), 4-aminopyrimidine (0.282 g), cesium carbonate (1.447 g), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.171 g), 1,4-dioxane (15 mL) and tris(dibenzylideneacetone)dipalladium (0.136 g) were added to a 35 mL microwave tube. The reaction system was sealed after nitrogen filling, and a CEM microwave reactor was set at 130 ° C and 100 W for 3 h. After the reaction was completed, the insoluble matter in the reaction solution was filtered. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to obtain 0.798 g of compound 16-1.

[0362] MS (ESI, [M+H] + )m / z:397.3.

[0363] Step B: Preparation of compound 16-2

[0364] The synthesis method is similar to that of step C in Example 1.

[0365] MS (ESI, [M+H] + )m / z:297.2.

[0366] Step C: Preparation of Compound 16

[0367] The synthesis method is similar to that of step D in Example 1.

[0368] 1 H NMR(500MHz,DMSO-d6)δ9.82(s,1H),8.69–8.65(m,2H),8.41–8.37(m,2H),7.94–7.89 (m,2H),7.85(d,J=8.5Hz,1H),7.81(d,J=5.8Hz,1H),6.77(d,J=7.5Hz,1H),6.68(s,1H ),6.30(s,1H),4.90(p,J=7.0Hz,1H),4.54(s,2H),3.70(d,J=13.0Hz,2H),3.05(d,J= 12.3Hz,2H),2.20(s,3H),1.94–1.87(m,2H),1.77–1.70(m,2H),1.41(d,J=7.1Hz,3H).

[0369] MS (ESI, [M+H] + )m / z:529.3.

[0370] Example 17: Preparation of Compound 17

[0371]

[0372] Step A: Preparation of Compound 17-1

[0373] The synthesis method is similar to that of Example 16, Step A.

[0374] MS (ESI, [M+H] + )m / z:427.4.

[0375] Step B: Preparation of Compound 17-2

[0376] The synthesis method is similar to that of Example 16, Step B.

[0377] MS (ESI, [MH] + )m / z:325.1.

[0378] Step C: Preparation of Compound 17

[0379] The synthesis method is similar to that of Example 16, Step C.

[0380] 1H NMR(500MHz,DMSO-d6)δ11.84(s,1H),8.65(d,J=4.3Hz,1H),8.37(s,1H),8.23(s ,1H),7.97–7.87(m,2H),7.84(d,J=8.5Hz,1H),6.80(d,J=7.4Hz,1H),6.32(s,1H ),6.22(s,1H),4.94–4.83(m,1H),4.65(s,2H),3.72(dd,J=11.4,5.4Hz,2H),3.0 5(d,J=12.2Hz,2H),2.20(s,3H),1.95(s,2H),1.75(s,2H),1.40(d,J=7.0Hz,3H).

[0381] MS (ESI, [M+H] + )m / z:559.3.

[0382] Example 18: Preparation of Compound 18

[0383]

[0384] Step A: Preparation of Compound 18-1

[0385] Add 2,4-dichloro-6-methylpyrimidine (3.49 g), 2-amino-5-fluoropyridine (2.0 g) and tetrahydrofuran (50 mL) to a 100 mL three-necked flask. After nitrogen replacement protection, place the reaction system in an ice-salt bath and cool it to below 0°C. Take potassium tert-butoxide (6.01 g) and disperse it in tetrahydrofuran (20 mL) to form a suspension, and slowly drip it into the reaction system using a syringe. After the addition, react at room temperature. After the reaction is completed, pour the reaction solution into purified water (300 mL) for dilution, extract the aqueous phase with ethyl acetate, and collect the organic phase. After drying, filtering, concentrating, and column chromatography purification, 1.291 g of compound 18-1 is obtained.

[0386] MS (ESI, [M+H] + )m / z:239.0.

[0387] Step B: Preparation of compound 18-2

[0388] The synthesis method is similar to that of step B in Example 1.

[0389] MS (ESI, [M+H] + )m / z:415.3.

[0390] Step C: Preparation of Compound 18-3

[0391] The synthesis method is similar to that of step C in Example 1.

[0392] MS (ESI, [M+H] + )m / z:315.2.

[0393] Step D: Preparation of Compound 18

[0394] The synthesis method is similar to that of step D in Example 1.

[0395] 1 H NMR(500MHz,DMSO-d6)δ9.82(s,1H),8.66(d,J=4.5Hz,1H),8.39(d,J=1.9Hz,1H),8.26(d,J=3.0H z,1H),7.99(dd,J=9.0,3.7Hz,1H),7.95–7.89(m,2H),7.86(d,J=8.5Hz,1H),7.70(td,J=8.8,3.1 Hz,1H),6.78(d,J=7.5Hz,1H),6.55(s,1H),4.91(p,J=7.0Hz,1H),4.68(s,2H),3.76(d,J=12.4Hz ,2H),3.01(d,J=12.4Hz,2H),2.20(s,3H),1.88(s,2H),1.75–1.68(m,2H),1.42(d,J=7.1Hz,3H).

[0396] MS (ESI, [M+H] + )m / z:547.5.

[0397] Example 19: Preparation of Compound 19

[0398]

[0399] Step A: Preparation of Compound 19-1

[0400] 2,4-dichloro-6-methylpyrimidine (1.104g), 5-fluorothiazole-2-amine hydrochloride (1.049g), N,N-diisopropylethylamine (2.63g), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.392g), 1,4-dioxane (15mL), tris(dibenzylideneacetone)dipalladium (0.310g) and potassium phosphate (3.59g) were added to a 35mL microwave tube. The reaction system was sealed after nitrogen filling, and the CEM microwave reactor was set to 130°C and 100W for heating reaction for 3h. After the reaction was completed, the insoluble matter in the reaction solution was filtered. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain 0.443g of compound 19-1.

[0401] MS (ESI, [M+H] +)m / z:245.0.

[0402] Step B: Preparation of compound 19-2

[0403] The synthesis method is similar to that of step B in Example 1.

[0404] MS (ESI, [M+H] + )m / z:421.3.

[0405] Step C: Preparation of Compound 19-3

[0406] The synthesis method is similar to that of step C in Example 1.

[0407] MS (ESI, [MH] - )m / z:319.2.

[0408] Step C: Preparation of Compound 19

[0409] The synthesis method is similar to that of step D in Example 1.

[0410] 1 H NMR(500MHz,DMSO-d6)δ11.33(s,1H),8.66(d,J=4.4Hz,1H),8.39(s,1H),7.93(d,J =8.0Hz,1H),7.90(d,J=4.1Hz,1H),7.85(d,J=8.5Hz,1H),7.23(d,J=2.2Hz,1H),6.7 9(d,J=7.5Hz,1H),6.09(s,1H),4.91(p,J=6.9Hz,1H),4.85–4.65(m,2H),3.79(s,2 H),3.15–2.92(m,2H),2.20(s,3H),1.93(s,2H),1.74(s,2H),1.42(d,J=7.0Hz,3H).

[0411] MS (ESI, [MH] - )m / z:551.2.

[0412] Example 20: Preparation of Compound 20-a and Compound 20-b

[0413]

[0414] Step A: Preparation of Compound 20-1

[0415] To a 250mL single-mouth bottle, add 2,4-dichloro-6-methylpyrimidine (4.11g), 4-aminopyrimidine (2g) and tetrahydrofuran (30mL) in sequence. Under nitrogen protection, cool the reaction system to 0°C and add potassium tert-butoxide (3.3g) in batches. After the addition is complete, transfer the reaction to room temperature and stir overnight. Stop stirring, remove the solvent under reduced pressure on a rotary evaporator, and add water (100mL) to the residue. After stirring at room temperature for 1h, filter, and remove the water from the filter cake by vacuum evaporation on a rotary evaporator. Add dichloromethane (100mL) to the residue, stir at room temperature for 1h, filter, wash the filter cake with 10mL×3 dichloromethane, collect the filter cake, and remove the organic solvent under reduced pressure on a rotary evaporator to obtain 360mg of compound 20-1.

[0416] MS (ESI, [M+H] + )m / z:222.1.

[0417] Step B: Preparation of Compound 20-2

[0418] Compound 20-1 (0.36 g) prepared in step A, 1-methoxy-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)cyclohexane-3-ene-1-carboxylic acid methyl ester (0.77 g), tetrakis(triphenylphosphine)palladium (0.188 g), potassium carbonate (0.561 g), 1,4-dioxane (6 mL) and water (1 mL) were added to a 30 mL sealed tube in sequence, stirred for 1 min, placed in a microwave reactor, heated to 125° C. at 50 W for 2 h. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain 360 mg of compound 20-2.

[0419] MS (ESI, [M+H] + )m / z:356.2.

[0420] Step C: Preparation of Compound 20-3

[0421] Compound 20-2 (360 mg) prepared in step B, 10% palladium hydroxide on carbon (142 mg) and methanol (5 mL) were added to a 100 mL eggplant-shaped bottle in sequence, and hydrogen was replaced and protected for 3 times, and the mixture was heated to 78°C for 48 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain 200 mg of compound 20-3.

[0422] MS (ESI, [M+H] + )m / z:358.3.

[0423] Step D: Preparation of Compound 20-4

[0424] In a 100 mL eggplant-shaped bottle, compound 20-3 (200 mg) prepared in step C, ethanol (6 mL) and tetrahydrofuran (6 mL) were added in sequence, followed by sodium hydroxide (67.1 mg) and water (1 mL). The mixture was reacted at 50 ° C for 5 h under nitrogen protection. After the reaction was completed, stirring was stopped and the pH was adjusted to acidic with 1 M hydrochloric acid. The solvent was evaporated under reduced pressure on a rotary evaporator to obtain 200 mg of a product containing compound 20-4, which was directly used in the next step without purification.

[0425] MS (ESI, [M+H] + )m / z:342.2.

[0426] Step E: Preparation of Compound 20-a and Compound 20-b

[0427] Compound 20-4 (200 mg) prepared in step D, (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethane-1-amine dihydrochloride (163 mg), 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate (455 mg), N,N-diisopropylethylamine (226 mg) and N,N-dimethylformamide (10 mL) were added to a 100 mL eggplant-shaped bottle in sequence, and reacted at room temperature for 1 h under nitrogen protection. 50 mL of ethyl acetate and 10 mL of water were added to the reaction system, extracted twice with 30 mL of ethyl acetate, the organic phase was collected, and the organic phase was washed three times with saturated brine. Drying over anhydrous sodium sulfate, filtering, and purifying the filtrate by column chromatography to obtain 58 mg of compound 20-a and 122 mg of compound 20-b.

[0428] Compound 20-a:

[0429] 1 H NMR(500MHz,DMSO d6)δ10.42(s,1H),8.77(s,1H),8.64(d,J=4.5Hz,1H),8.41-8.48(m,3H),7.97(d,J=10.7Hz,1H),7.84-7.90(m,3H),7.33(s, 1H),5.05-5.11(m,1H),3.09(s,3H),2.81(br,1H),2.34(s,3H),1.88-2.19(m,6H),1.52-1.57(m,2H),1.46(d,J=7.1Hz,3H).

[0430] HRMS (ESI, [M+H] + )m / z:532.2585;

[0431] Compound 20-b:

[0432] 1 H NMR (500MHz, DMSO-d6) δ10.47(s,1H),8.81(s,1H),8.68(d,J=4.4Hz,1H),8.48-8.52(m,2H),8.43(d,J=2.0Hz,1H),7.98-8.01(m,1H) ,7.83-7.92(m,3H),7.45(s,1H),5.03-5.09(m,1H),3.14(s,3H),2.70(br,1H),2.37(s,3H),1.62-2.02(m,8H),1.47(d,J=7.1Hz,3H).

[0433] HRMS (ESI, [M+H] + )m / z:532.2585.

[0434] Example 21: Preparation of Compound 21

[0435]

[0436] Step A: Preparation of Compound 21-1

[0437] Add 2,4-dichloro-6-methylpyrimidine (3.49 g), 2-amino-5-fluoropyridine (2.0 g) and tetrahydrofuran (50 mL) to a 100 mL three-necked flask in sequence. After nitrogen replacement protection, place the reaction system in an ice-salt bath and cool it to below 0°C. Take potassium tert-butoxide (6.01 g) and disperse it in tetrahydrofuran (20 mL) to form a suspension, and slowly drip it into the reaction system using a syringe. After the addition, react at room temperature. After the reaction is completed, pour the reaction solution into purified water (300 mL) for dilution, extract the aqueous phase with ethyl acetate, collect the organic phase, and obtain 1.291 g of compound 21-1 after drying, filtering, concentrating, and column chromatography purification.

[0438] MS (ESI, [M+H] + )m / z:239.0.

[0439] Step B: Preparation of Compound 21-2

[0440] Compound 21-1 (0.5 g) prepared in step A, a mixed solution of dioxane (10 mL) and water (2 mL), 1-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) cyclohex-3-ene-1-carboxylic acid methyl ester (0.62 g) and potassium carbonate (0.73 g) were added to a 35 mL microwave tube in sequence. Nitrogen was blown for 2 min, and tetrakis(triphenylphosphine)palladium (0.12 g) was quickly added. After stirring for 10 s, it was placed in a microwave reactor, heated to 125 ° C, and reacted for 2 h. After the reaction was completed, 10 mL of water was added to the reaction solution, and extracted with ethyl acetate (20 mL × 3), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was added to 50 mL of dichloromethane for redissolution, silica gel sand making, and separation and purification by chromatography column. The eluate containing the target compound was collected and concentrated, and the organic solvent was removed using an oil pump to obtain 0.5 g of compound 21-2.

[0441] MS (ESI, [M+H] + )m / z:373.2.

[0442] Step C: Preparation of Compound 21-3

[0443] In a 25 mL single-mouth bottle, compound 21-2 (0.445 g), ethanol (5 mL), and palladium / carbon (10.6 mg) prepared in step B were added in sequence, and the hydrogen gas was replaced three times. The reaction was allowed to react overnight in an oil bath at 75°C. The reaction lasted for about 22 hours until the reaction was complete. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain 0.26 g of compound 21-3, which was used directly in the next step without purification.

[0444] MS (ESI, [M+H] + )m / z:375.2.

[0445] Step D: Preparation of Compound 21-4

[0446] In a 25mL single-mouth bottle, add the compound 21-3 (0.26g) prepared in step C, a mixed solution of ethanol (6mL) and tetrahydrofuran (6mL) and an aqueous solution of sodium hydroxide (0.278g) (made into a 1M aqueous solution), heat to 60°C, and stir for 10h. The reaction is basically complete. Slowly drop a 1M aqueous solution of hydrochloric acid (7.5mL) into the reaction system. Make the reaction solution weakly acidic (the molar ratio of acid to base is 1.25). The reaction solution is directly concentrated, and the concentration conditions are: 55°C, 23mbar, and then concentrated by an oil pump. 0.44g of the product containing compound 21-4 is obtained, which is directly used in the next step without purification.

[0447] MS (ESI, [MH] - )m / z:359.3.

[0448] Step E: Preparation of Compound 21

[0449] Compound 21-4 (0.25 g) prepared in step D, N, N-dimethylformamide (15 mL), (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl-1-amine dihydrochloride (0.198 g), N, N'-diisopropylethylamine (0.561 g) and 2-(7-benzotriazole oxide)-N, N, N', N'-tetramethyluronium hexafluorophosphate (0.409 g) were added to a 25 mL single-mouth bottle in sequence, and stirred at room temperature for 3.5 h. 10 mL of water was added to the reaction system, extracted twice with 50 mL of ethyl acetate, the organic phase was collected, and the organic phase was washed three times with saturated brine (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated, and the concentrate was redissolved with 20 mL of dichloromethane, silica gel sand was made, and column chromatography was purified. The eluate was collected and concentrated to obtain 0.15 g of a mixture of compound 21 and its cis-configuration. The trans-configuration was prepared and resolved to finally obtain 77 mg of compound 21.

[0450] 1 H NMR (500MHz, DMSO-d6): δ10.07(s,1H),8.68(d,J=4.5Hz,1H),8.45(m,2H),8.29(s,1H),7.90(m,4H),7.69(m,1H ),7.31(s,1H),5.06(d,J=7.0Hz,1H),3.13(s,3H),2.64(s,1H),2.32(s,3H),1.85(m,8H),1.47(d,J=7.0Hz,3H).

[0451] HRMS (ESI, [M+H] + )m / z:549.2526.

[0452] Example 22: Preparation of Compound 22

[0453]

[0454] Step A: Preparation of Compound 22-1

[0455] The synthesis method was similar to that of step A in Example 1 to obtain compound 22-1.

[0456] 1H NMR (500MHz, DMSO-d6): δ10.87(s,1H),8.84(s,1H),8.35(dd,J=1.5Hz,2.5Hz,1H),8.25(d,J=2.5Hz,1H),7.62(s,1H),2.37(s,3H).

[0457] MS (ESI, [M+H] + )m / z:222.1.

[0458] Step B: Preparation of Compound 22-2

[0459] The synthesis method was similar to that of Example 21, Step B, to obtain compound 22-2.

[0460] MS (ESI, [M+H] + )m / z:356.5.

[0461] Step C: Preparation of Compound 22-3

[0462] The synthesis method was similar to that of step C in Example 21 to obtain compound 22-3.

[0463] MS (ESI, [M+H] + )m / z:358.2.

[0464] Step D: Preparation of Compound 22-4

[0465] The synthesis method was similar to that of Step D in Example 21 to obtain Compound 22-4.

[0466] MS (ESI, [MH] - )m / z:342.1.

[0467] Step E: Preparation of Compound 22

[0468] The synthesis method was similar to that of Example 21, Step E, to prepare Compound 22.

[0469] 1 H NMR (500MHz, DMSO-d6): δ10.33(s,1H),9.16(s,1H),8.68(d,J=4.5Hz,1H),8.46(m,3H),8.19(d,J=2.5Hz,1H),7.92(m, 3H),7.35(s,1H),5.06(m,1H),3.13(s,3H),2.66(m,1H),2.35(s,3H),1.95(m,2H),1.80(m,6H),1.47(d,J=7.0Hz,3H).

[0470] HRMS (ESI, [M+H] + )m / z:532.2585.

[0471] Experimental Example 1: Inhibitory activity of in vitro kinases RET, RET(V804M) and TT cells

[0472] 1.1 RET inhibitory activity screening

[0473] 50 ng / μL RET stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), 6 μl of 1.67× 0.000334 ng / μl working solution was added to each well (final concentration was 0.0002 ng / μl), and different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound be 1000 nM-0.24 nM, 4-fold gradient, a total of 7 concentrations, and blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0474] 1.2 Screening of RET(V804M) inhibitory activity

[0475] 50 ng / μL RET (V804M) stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μl of 1.67× 0.0835 ng / μl working solution was added to each well (final concentration was 0.05 ng / μl). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound be 1000 nM-0.24 nM, with a 4-fold gradient and a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0476] 1.3 Inhibitory effect of compounds on TT cell proliferation

[0477] Take TT cells (Nanjing Kebai Biotechnology Co., Ltd.) in good exponential growth phase, wash twice with PBS, stop digestion with trypsin for 2-3 minutes, collect cells into centrifuge tubes, centrifuge at 1000 rpm for 5 minutes, discard supernatant, add 4 mL seed culture medium (F12K basal medium + 5% FBS + 1% glutamine) with a pipette to resuspend cells. Count with a cell counter, dilute with seed culture medium, and adjust cell density to 2*10 5 / mL. Use a multichannel pipette to inoculate on a 96-well plate, 100μL / well, and culture in a cell culture incubator at 37°C and 5% CO2 saturated humidity. After 24 hours of culture, use a nanoliter pipette to add the compound, set up 2 replicates for each concentration, and use cells without compound as negative control. After 120 hours, add CCK-8, 10μL / well, and 3 hours later, use Envision microplate reader to detect its absorbance at 450nm, and calculate the inhibition rate. Inhibition rate (%) = (average value of negative control group - average value of experimental group) / (average value of negative control group - average value of blank group) × 100%, with the logarithm of compound concentration as the horizontal axis and inhibition rate as the vertical axis. Four-parameter analysis, fitting of dose-effect curve, and calculation of IC 50 .

[0478] 1.4 The activity results of in vitro kinase RET, RET(V804M) and TT cells are shown in Table 1.

[0479] Table 1

[0480]

[0481] “--” means not detected.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in, U, V and W are each independently selected from CH or N, and at least one of U, V and W is selected from N; Ring B is selected from an 8-membered bridged heterocyclic ring containing 2 N atoms; R 1 , R 7 are each independently selected from H, cyano, hydroxyl, halogen, C 1-6 Alkyl or C 1-4 Haloalkyl; R 2 Selected from H, cyano, hydroxyl, halogen, C 1-6 Alkyl or C 1-4 Haloalkyl; Every R 3 are independently selected from cyano, halogen, C 1-6 Alkyl, C 1-4 Haloalkyl or C 1-6 Alkoxy; R 4 , R 5 are each independently selected from H, halogen or C 1-6 alkyl; R 6 Selected from H, halogen, cyano, hydroxyl, C 1-6 Alkyl or C 1-4 Haloalkyl; n is 0, 1 or 2.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein W is selected from CH, and U and V are both selected from N; or W is selected from CH, V is selected from CH, and U is selected from N.

3. The compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 7 are each independently selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

4. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 3, wherein R 1 Selected from H, R 7 Selected from H, F, cyano or methyl.

5. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 4, wherein R 1 Selected from H, R 7 Selected from cyano and methyl.

6. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 5, wherein R 1 Selected from H, R 7 Selected from cyano.

7. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R 2 Selected from H, cyano, halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

8. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 7, wherein R 2 Selected from methyl or trifluoromethyl.

9. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 8, wherein R 2 Selected from methyl.

10. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein each R 3 are independently selected from cyano, halogen, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkoxy.

11. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 10, wherein each R 3 Each independently selected from C 1-3 Alkyl or C 1-3 Alkoxy.

12. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 11, wherein each R 3 Each is independently selected from methyl or methoxy.

13. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 12, wherein each R 3 are each independently selected from methyl.

14. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R 4 , R 5 are each independently selected from H, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

15. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 14, wherein R 4 , R 5 Each independently selected from H or C 1-3 Alkyl, the C 1-3 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

16. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 15, wherein R 4 , R 5 Each is independently selected from H or methyl.

17. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 16, wherein R 4 Selected from H, R 5 is selected from methyl; or, R 4 Selected from methyl, R 5 Selected from H.

18. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R 6 Selected from H, halogen, cyano, C 1-3 Alkyl or C 1-3 Halogenated alkyl.

19. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 18, wherein R 6 Selected from halogen or C 1-3 alkyl.

20. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 19, wherein R 6 is selected from fluorine, chlorine, bromine or iodine.

21. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 20, wherein R 6 Selected from fluorine.

22. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein ring B is selected from 23. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 22, wherein ring B is selected from 24. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the structural unit Selected from 25. The compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 24, wherein the structural unit Selected from 26. The following compounds, or pharmaceutically acceptable salts thereof, 27. A pharmaceutical composition comprising the compound according to any one of claims 1 to 26 or a pharmaceutically acceptable salt thereof.

28. Use of a compound according to any one of claims 1 to 26, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 27 in the preparation of a medicament for preventing or treating a disease mediated by abnormal RET activity, wherein the disease mediated by abnormal RET activity is cancer, and the cancer is selected from papillary thyroid cancer, medullary thyroid cancer, pheochromocytoma, pancreatic cancer, multiple endocrine neoplasia, breast cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, blood tumors, colorectal cancer, ovarian cancer, cervical cancer, gastric cancer, prostate cancer, and salivary gland cancer.

Citation Information

Patent Citations

  • Fused ring compound, pharmaceutical composition containing fused ring compound, and preparation method and application of fused ring compound

    CN111285882A

  • 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

    US20180022731A1

  • Compounds useful for treating disorders related to ret

    US20180022732A1